How to Use Rentox for Crow’s Feet | Mechanism, Dosage, and Efficacy Rates

For crow’s feet, Rentox relaxes the orbicularis oculi muscle by blocking neurotransmitters.

The conventional total dose is 12-24 units, administered via subcutaneous injection at 3 points: 2-4 units per point, at least 1 cm lateral to the orbital rim.

Clinical data show that the effect begins 48-72 hours after injection, with an efficacy rate of over 90%.

The effect peaks at 14 days and can last for 3-5 months, restoring the skin at the corners of the eyes to a smooth and youthful state.

Mechanism

Rentox is a high-purity Botulinum Toxin Type A that primarily blocks nerve conduction through a 150kDa protein complex.

The process involves the binding of molecules to nerve terminal receptors and the cleavage of the SNAP-25 protein within the cytoplasm.

This action halts the exocytosis of acetylcholine, causing the orbicularis oculi muscle to relax within 2-3 days.

Clinical tests indicate that its 99.8% protein purity effectively controls the diffusion range. At a dose of 12-24U, it can maintain stable muscle relaxation for 12 weeks or even longer.

Molecular Level

Rentox contains a 150kDa active neurotoxin. After reconstitution, the 100kDa heavy chain seeks out and locks onto the SV2 receptors of nerve endings. Subsequently, in an environment of pH 5.0, the 50kDa light chain penetrates the cytoplasm and physically cleaves the SNAP-25 protein, which consists of 206 amino acids, reducing acetylcholine release by more than 80%. Usually, an injection volume of 12-24U can induce deep relaxation of the orbicularis oculi muscle within 14 days and maintain a smooth effect for 4 months.

Rentox utilizes a vacuum-drying process in production, achieving a protein purity of over 99.8%, providing a stable biochemical foundation for subsequent molecular-level reactions. After the drug solution is injected into the periocular tissue, the distribution density of the molecules determines the binding efficiency with the neuromuscular junction. The active molecules dissociate in the interstitial space and quickly come into contact with the presynaptic membrane of motor neurons.

The heavy chain portion of the molecule has extremely strong targeting capabilities, specifically identifying and adsorbing onto Synaptic Vesicle Protein 2 (SV2) receptors on the surface of nerve cells. Since the binding affinity reaches the nanomolar level, the active ingredients in the drug solution can precisely cover millions of nerve terminal sites. Within 30 minutes after physical adsorption is complete, the nerve cell membrane produces an endocytic reaction.

The aforementioned binding action induces endocytosis in the nerve cell, wrapping Rentox molecules into vesicles approximately 50 nanometers in diameter and bringing them inside the cell. As the vesicles move within the cytoplasm, the internal acidity fluctuates drastically, with the pH dropping from the physiological state of 7.4 to around 5.0. The acidic environment forces the 100kDa heavy chain to change its molecular conformation, opening a micro-channel on the vesicle membrane.

The disulfide bonds within the 150kDa molecule break under this physical environment, releasing the 50kDa light chain portion to pass through the channel into the cytoplasm. This light chain is essentially a zinc-ion metalloprotease whose sole task is to find and destroy a transport protein called SNAP-25. This protein, composed of 206 amino acids, is an indispensable physical scaffold in the process of nerve signal release.

1. The 100kDa heavy chain exhibits extremely high binding precision with nerve endings.
2. Molecules completely enter the interior of the neuron through endocytosis within 30 minutes.
3. The 50kDa light chain moves freely in the cytoplasm as an enzymatic agent to find targets.
4. The SNAP-25 protein is physically cleaved between the 197th and 198th amino acids.
5. After injecting 0.1 ml of diluent, the diffusion diameter is restricted to approximately 1.5 cm.
6. The single effective concentration can maintain activity within the nerve ending for 90 to 120 days.

Because the SNAP-25 protein is physically cleaved, the acetylcholine vesicles responsible for transporting nerve signals cannot fuse with the cell membrane of the nerve ending. In a normal state, each signal pulse releases about 5,000 to 10,000 acetylcholine molecules, but under the interference of Rentox, this release volume drops below 20% of the baseline. The physical interruption of signal conduction results in the orbicularis oculi muscle failing to receive contraction commands issued by the brain.

After losing chemical drive, the orbicularis oculi muscle enters a passive state of relaxation, no longer producing sharp squeezing motions due to facial expressions. Clinical observations show that within the first 72 hours after injection, dynamic wrinkles around the eyes begin to fade, reaching the physiological peak of muscle paralysis on the 14th day. At this stage, the muscle discharge frequency is at its lowest level, providing a physical environment for the dermis layer to self-repair.

1. The SNARE complex assembly process is completely blocked by the protease.
2. Vesicles with a diameter of 40 nanometers cannot release signals due to the loss of the protein scaffold.
3. Electromyography (EMG) shows a decrease of more than 75% in the contraction frequency of the eye corner muscles.
4. Nerve endings re-establish signal connections through axonal sprouting after 12 weeks.

Over time, the cleaved proteins are metabolized by the cell, and new SNAP-25 proteins are re-synthesized; muscle strength usually begins to recover slowly around 16 weeks. This high-purity formula ensures a single metabolic pathway, avoiding unnecessary tissue inflammatory reactions.

Transmission Blockage

Rentox physically cleaves the SNAP-25 protein within nerve endings, causing acetylcholine vesicles with a diameter of 50 nanometers to lose their fusion scaffold.

Chemical signals that originally contained 10,000 molecules cannot cross the synaptic cleft, resulting in a reduction of nerve drive efficiency by more than 80%.

Under the intervention of a 12-24U dose, the electrophysiological activity of the orbicularis oculi muscle weakens within 72 hours, allowing the skin at the corners of the eyes to reach a smooth state within 14 days.

After Rentox enters the neuronal cytoplasm, the 150kDa light chain portion exhibits extremely strong protease activity. This molecule locates and adsorbs onto the SNAP-25 protein, composed of 206 amino acids, which is the physical basis for maintaining signal transmission. As this protein chain is physically cut between the 197th and 198th positions, the release mechanism of the nerve ending fundamentally changes.

Once the physical structure is destroyed, the Syntaxin protein on the presynaptic membrane and the VAMP protein on the vesicle membrane lose their docking bridge. Since the SNARE complex cannot be assembled normally, nerve signals cannot be converted into the chemical power that drives muscle contraction.

Normal nerve conduction is completed within 0.1 milliseconds via electrochemical signal conversion, but under the effect of the drug, this conversion channel is closed.

Vesicles with a diameter of 40-50 nanometers, originally lined up near the release sites, lose the mechanical energy to move toward the cell membrane. Due to the lack of a complete protein scaffold support, the vesicles cannot complete the membrane fusion process, causing the stored chemical substances to be locked inside the neuron.

1. The SNAP-25 protein chain undergoes irreversible physical breakage at the molecular level.
2. The assembly success rate of the SNARE complex drops below 15% of the baseline.
3. The 150kDa light chain acts as a catalyst and can continue to work within a single nerve ending for several weeks.
4. The 40 nanometer acetylcholine vesicles accumulate near the presynaptic membrane due to the loss of tension.
5. The chemical release peak excited by a single nerve electrical pulse drops sharply within 48 hours.

In an un-intervened physiological state, each release pulse contains approximately 10,000 acetylcholine molecules, which are responsible for turning on the contraction switch of muscle fibers. Once the drug takes effect, the amount of signal reaching the muscle receptors per unit time is no longer sufficient to trigger physical deformation.

With the loss of chemical driving force, the muscle fiber tension of the orbicularis oculi transitions from a contracted state to a passive relaxed state. This state is reflected externally as the dermis in the eye corner area no longer being subjected to repeated squeezing from the deep muscles.

Laboratory electrophysiological monitoring shows that after a 12U dose, the amplitude of the end-plate potential of the target muscle decreased by about 85%.

This physical blockage has extremely high spatial distribution precision, with the diffusion diameter usually maintained within a range of 1.5 cm. This range ensures that only the acetylcholine transmission in the target area is inhibited, without affecting the deeper ocular regulatory muscles.

1. A conventional dose of 12-24U can cover about 3-5 major nerve plexus branches around the eyes.
2. An acidic environment of pH 5.0 is the biochemical switch that initiates the light chain’s cleavage action.
3. Zinc ions serve as catalytic cofactors, assisting the light chain in precisely locating the cleavage site of SNAP-25.
4. After 14 days, the nerve signal blockage efficiency in the target area reaches its physiological peak.

Because acetylcholine cannot be released smoothly, communication between the nerve and the muscle enters a silence period lasting 12-16 weeks. During this period, although the brain continues to issue contraction commands, the orbicularis oculi muscle remains at a low tension level, providing physical space for the smoothing of skin wrinkles.

This blocking process is not permanent; the nervous system initiates a self-repair program. As old nerve ending functions degrade, new nerve branches extend toward the muscle in a “sprouting” manner, attempting to re-establish chemical signal pathways.

The growth rate of nerve sprouts is approximately 1-2 mm per day, which determines the natural pattern of the effect gradually fading after 4 months.

Under the protection of this mechanism, the skin surface avoids tens of thousands of repeated folding motions over several months. The high-purity molecular formula reduces the probability of antibody production, ensuring that the blocking efficiency can still maintain over 90% in subsequent maintenance procedures.

1. More than 80% of the acetylcholine release pathways are completely physically blocked within one week after injection.
2. The 150kDa active molecule is naturally degraded by cellular lysosomes after completing its cleavage task.
3. The 100kDa heavy chain completes precise occupancy of the target nerve endings in the early stage of binding.
4. The 20% residual signal volume only maintains the basic physiological metabolism of the muscle, insufficient to produce expression wrinkles.

The fan-shaped controlled area on the outer side of the eye thus achieves a dynamic balance, preserving subtle natural expressions while eliminating moderate to severe skin creases. This transmission blockage based on molecular cleavage is the biochemical cornerstone for achieving physical improvement in periocular rejuvenation.

Motor Control

After entering the periocular tissue, Rentox regulates the Orbicularis Oculi muscle at a physical level through its high-purity 150kDa active molecules. Under a 0.1 ml dilution gradient, the diffusion diameter of the molecule is strictly limited to a range of 1.0-1.5 cm, ensuring that only the muscle tension in the controlled area is changed. After a 12-24U dose is injected, the electrophysiological activity of local muscle fibers will show visible attenuation within 24-72 hours.

Since Rentox removes excess impurity proteins, the penetration path of the active ingredients in the tissue shows high predictability. By identifying the SV2 receptors of motor nerve endings, the molecule physically blocks the transmission process of nerve electrical signals to the muscle. The target area of the orbicularis oculi belongs to a region dense with fast-twitch muscle fibers, which are extremely sensitive to changes in acetylcholine concentration.

Laboratory data show that about 14 days after injection, the contraction amplitude of the local muscle will decrease by about 75%-85%. This process causes the fan-shaped muscle group in the eye corner area to enter a controlled quiescent period, reducing the repeated folding pressure on the skin covering it.

1. The 99.8% purity formula reduces the chance of receptor binding in non-target areas.
2. The 1.5 cm diffusion radius effectively avoids physical impact on the levator palpebrae superioris muscle.
3. The 150kDa molecule achieves an occupancy rate of up to 90% at the neuromuscular junction.
4. The total amount of 12-24U is distributed across 3-5 major sites on both sides to maintain tension balance.
5. After 72 hours, the discharge frequency shown by local EMG shows a significant downward shift.
6. The pH 5.0 internal environment triggers the physical cleavage of proteins in the signal pathway by the light chain.

With the closing of the acetylcholine release channel, the fibers of the orbicularis oculi muscle remain in a relaxed state, no longer shortening due to expression activities. This state is reflected in the epidermis as the disappearance of dynamic crow’s feet and the relief of pressure on the dermis.

Electrophysiological monitoring reflects that after giving the standard dose intervention, the amplitude of the end-plate potential dropped from the normal 30-40mV to below 5mV.

Once the physical barrier to signal transmission is established, the contraction force of muscle fibers remains at an extremely low level for 12 weeks. During this period, the skin around the eyes can undergo physiological metabolism and repair in an environment free of squeezing, helping to alleviate static lines formed by long-term folding.

Over time, blocked nerve endings will generate new synaptic branches through “axonal sprouting,” attempting to find unoccupied receptors. This biological self-repair speed is usually maintained at 1-2 mm per day, which determines the natural regression process of the motor control effect. Usually, at around 4 months, the newly generated connections are sufficient to re-drive muscle contraction.

Due to Rentox’s excellent molecular stability, the coefficient of variation of its biological activity after reconstitution is controlled within 5%. This allows the number of units in each injection to be precisely converted into the expected depth of muscle relaxation, reducing the risk of expression asymmetry caused by uneven drug efficacy.

1. After the SNAP-25 protein is physically cut, the signal pathway of the nerve ending is completely closed.
2. The 100kDa heavy chain completes the locking of millions of receptor sites in the early stage of binding.
3. The 20% residual electrical signal can only maintain the basic metabolism of muscle fibers, insufficient to induce contraction.
4. After 14 days, the electrophysiological activity in the eye corner area enters a stable “quiescent period.”
5. The 0.1 ml single-point volume ensures uniform distribution of the drug solution in the tissue space.

The motor regulation of the orbicularis oculi by the drug solution is not limited to surface dynamic improvement; it also changes the biomechanical environment of local tissues by reducing the resting tension of the muscle. When a subject attempts an eye-squeezing motion, the muscle fibers cannot physically respond to the brain’s command due to the interruption of the chemical signal chain.

This process completes the reprogramming of mechanical motion at the molecular level, converting high-frequency squeezing into stable tension release. The high-purity product characteristics reduce the inflammatory background within the tissue, making the metabolic environment within the muscle during the relaxation period more stable, providing biochemical assurance for long-term smoothing effects.

Tissue section observation shows that during the controlled period, the diameter of muscle fibers did not undergo pathological changes, showing only physical functional dormancy.

As nerve sprouts mature and new proteins are synthesized, muscle function will return slowly in a stepped manner rather than failing suddenly. This slow recovery curve ensures that visual changes around the eyes remain within a predictable range of fluctuation, avoiding visual abruptness.

1. The 150kDa active chain is naturally metabolized and decomposed by lysosomes after completing the cleavage task.
2. 120 days is the time point when most subjects observe the beginning of the return of physical tension.
3. Muscles outside the 1.5 cm diffusion circle still maintain 100% nerve control.
4. The protein chain composed of 206 amino acids loses its function as an assembly scaffold after cleavage.

Dosage

When treating crow’s feet, the standard total dose of Rentox is 24 Units, which means 12 Units are injected around each eye.

In clinical practice, these 12 Units are usually divided into 3 injection points, with 4 Units injected per point.

After dilution with 0.9% sodium chloride solution, the single-point injection volume is precisely controlled at 0.1 ml to ensure that the diffusion radius of the drug solution in the lateral orbicularis oculi is maintained between 0.5-1.0 cm, preventing the drug from diffusing to the inner canthus and causing diplopia.

Drug Solution Ratio Standards

Rentox belongs to the 900kDa type A botulinum toxin and is produced using vacuum-drying technology. Each 100 Units vacuum vial contains high-purity protein components. Before preparation, 0.9% sodium chloride (saline) must be prepared as a diluent. The pH of the saline should be maintained between 4.0 and 6.5 to ensure the biological activity of the toxin molecules.

During operation, saline should be drawn through an 18G needle. Place the needle tip against the inner wall of the Rentox vial and rely on the negative pressure inside the vial to automatically draw in the liquid.

For the common 100 Units specification, the following table shows the relationship between different saline addition amounts and the corresponding concentration:

When processing the 200 Units large package, the amount of saline added should be doubled. Diluting 200 Units of powder with 5.0 ml of saline yields the same 4.0 Units / 0.1ml concentration as shown in the table above. This ratio is the most commonly used in crow’s feet treatment. Precise concentration allows the diffusion rate of the drug solution in the orbicularis oculi to be controlled at approximately 0.1 mm per hour.

After the liquid injection is complete, violent shaking of the vial is strictly prohibited. The correct way is to hold the vial and rotate it slowly at a speed of 2 to 3 circles per second for 30 seconds until the white powder at the bottom completely disappears, forming a transparent solution.

In addition to the basic ratio, the volume loss of injection tools is also an important factor affecting the actual dosage:

• Low dead space syringes: Using an integrated 31G needle can control residual drug solution to below 0.01 ml.
• Common needle loss: Conventional needle connections will retain approximately 0.08 ml of drug solution, equivalent to wasting 3.2 Units of dose.
• Scale precision: Syringes with a minimum scale of 0.01 ml must be selected to ensure that the injection volume error is within 5%.
• Injection resistance: Thin needles under high-concentration ratios have a heavier injection feel; a constant hand pressure must be maintained to prevent rapid push.

Under experimental conditions with an ambient temperature of 20 to 25 degrees Celsius, the activity of diluted Rentox decreases over time. Although clinical advice is to use it within 24 hours, studies have shown that there is almost no attenuation of activity within 4 hours when stored in a refrigerated environment of 2 to 8 degrees Celsius.

The prepared drug solution is isotonic, with an osmotic pressure of approximately 285 mOsm/L. This is consistent with human tissue osmotic pressure, which can significantly reduce the pain during injection. Given the thin nature of periocular skin, a 2.5 ml dilution ratio can prevent excessive local tension, reducing the post-treatment swelling sensation around the eyes.

Regarding risk prevention in the preparation process, the following operational details can effectively improve the stability of the drug solution:

1. Temperature pre-cooling: Saline taken from the refrigerator should be placed at room temperature for 5 minutes to avoid protein inactivation caused by excessive temperature differences.
2. Negative pressure detection: If the saline is not automatically sucked in after the needle is inserted, it indicates the vial has lost its vacuum and activity may be compromised.
3. Dark storage: The diluted drug solution is sensitive to UV light and should be stored in the original box or a black shading bag.
4. Aseptic control: The vial stopper should be wiped with 75% alcohol before and after puncture, and a new needle should be used for each draw.
5. Single patient per vial: To reduce infection risk, it is recommended that one vial be used for only one patient, and the remaining part is not recommended for cross-day storage.

If 24 Units are planned for injection, and 0.05 ml is lost due to bubble discharge in the syringe, the corresponding volume needs to be replenished. This strict control over data keeps the error of the drug dose on each side of the eye within 1 Unit.

For cases of eye asymmetry, the flexibility of the preparation concentration comes into play. For example, if crow’s feet on one side are deeper, a drug solution prepared with a 2.0 ml ratio can be used. This way, under the same injection volume, that side can receive a higher unit density. The shallower side maintains the standard 2.5 ml ratio.

A lower dilution amount (such as 1.0 ml) makes the drug solution slightly more viscous, which helps lock the drug at the injection point. This is very effective for areas requiring precise control of facial expression muscles. Conversely, a high dilution is suitable for improving large areas of fine dry lines.

The sodium ion concentration of physiological saline has a certain restrictive effect on the diffusion of toxin molecules. Using pure water or glucose solution as a diluent will cause the diffusion range to go out of control, significantly increasing the probability of the drug solution entering the intraorbital muscles. Therefore, only physiological saline for injection that meets USP (United States Pharmacopeia) standards is clinically permitted.

In the final step before injection, the physician will tap the syringe to discharge bubbles larger than 0.1 mm in diameter. The entry of air will change the pressure distribution inside the syringe, resulting in inaccurate feedback during injection. Ensure a drop of crystal-clear drug solution overflows at the needle tip, indicating that the air has been evacuated.

Injection Site Positioning

The thickness of periocular skin is usually only 0.5 mm, while the underlying orbicularis oculi muscle is about 1.2 mm thick. When locating the first point, mark it 1.5 to 2.0 cm laterally from the outer canthus. This position avoids the lateral incisor vein, reducing the probability of bruising by 80%.

By touching with the finger pad to locate the lateral orbital rim, all operating points must be maintained at 1.0 cm outside the bone rim. This safety distance prevents Rentox solution from penetrating inward into the eye socket. If the drug accidentally touches the muscles controlling eye rotation, it may cause diplopia lasting 2 to 4 weeks.

The selection of the upper coordinate point must avoid the lower edge of the frontalis muscle, with the distance maintained at 1.5 cm or more. If this point is too high, the drug solution may restrict the natural lifting action of the frontalis muscle, causing the outer eyebrow to droop by about 2 mm, making the expression look suppressed.

The positioning of the lower coordinate point must be extra cautious and must be above the origin of the zygomaticus major muscle. Maintaining a vertical distance of 1.0 cm ensures that the smile is not interfered with. If the drug solution diffuses downward by more than 1.5 cm, it may cause the corners of the mouth to fail to lift symmetrically during a smile.

The three positioning points form a C-shaped arc opening outward, with a total arc length of about 2.5 to 3.0 cm. This distribution can cover 95% of the dynamic wrinkle area. The dose at each point is 4 Units, ensuring uniform concentration distribution of the drug in the muscle fibers.

• Skin Marking: Use a surgical marker with a diameter of 0.5 mm to precisely mark the centers of the three coordinates before needle entry.
• Bone Sensation Confirmation: The index finger must repeatedly press the edge of the eye socket to perceive the bone transition, ensuring the marking point is not on the inside of the bone rim.
• Vessel Avoidance: Look for superficial blue-purple veins under intense light; points should deviate from the vessel center by 2 mm.
• Symmetry Measurement: Use a millimeter scale to measure the distance from the lateral canthus to the central point on both eyes; the error should be controlled within 0.5 mm.
• Dynamic Testing: Ask the subject to squeeze their eyes hard to observe whether the deepest part of the wrinkles completely coincides with the preset 3 points.
• Avoid Tarsal Plate: The lower positioning point must not be near the edge of the lower eyelid; a vertical safety zone of 1.5 cm must be maintained.

The needle entry angle should be maintained at a 20-degree angle to the skin surface, with the bevel facing up. This angle allows the drug solution to be precisely deposited in the shallow muscle 2 to 3 mm below the skin. Shallow administration allows the drug to complete initial absorption within 6 hours, reducing the risk of deep migration.

Measurements show that when the orbicularis oculi muscle contracts, the outer fibers will shorten toward the center by about 15% to 20%. Positioning points must be completed in a static state to reflect true anatomical spacing. If positioned according to the tail of the wrinkles, it often leads to the drug being administered away from the main body of the muscle.

For subjects with obvious fan-shaped wrinkles, the central point can be slightly adjusted outward by 3 mm. This adjustment expands coverage for long wrinkles while increasing the physical distance from the eye socket. According to fluid dynamics calculations, this 3 mm offset can reduce drug penetration pressure by 10%.

For cases with extremely loose periocular skin, the positioning points should be shifted upward as a whole by 2 mm. Gravity will cause the subcutaneous drug solution to undergo a slight downward shift within 30 minutes after injection. The reserved compensatory displacement ensures that the drug is ultimately distributed at the ideal muscle target.

During the procedure, the auxiliary hand should pull the skin diagonally outward and upward, maintaining a tension of about 50 gram-force. A flat skin surface improves the visual accuracy of positioning. After releasing the tension, verify whether the coordinate points have returned to the preset geometric center.

After each injection is completed, a temporary wheal (papule) about 3 mm in diameter will form at the coordinate center. The center of this wheal should completely overlap with the marker point. If the wheal shifts, it indicates the entry angle was too large, and an angle correction is needed at the next point.

This positioning mode based on geometric coordinates can reduce human error to within 1 mm. Through digitized management of the orbital rim, vascular pathways, and adjacent muscle groups, Rentox’s range of action is restricted to specific physical spaces.

Dosage Variation Fine-tuning

The standardized 24 Units total amount is a baseline reference value. In actual operation, it needs to be increased or decreased by 15% to 30% according to the contraction strength of the orbicularis oculi. For subjects with a muscle cross-sectional area exceeding 1.2 square centimeters, a dose of 12 Units per side often only produces about 60% relaxation, failing to completely smooth deep wrinkles.

The decision to increase the dose is based on the bulge height during dynamic contraction. If the local skin bulge exceeds 1.5 mm during muscle contraction, it is determined to be a strong-type muscle. In this case, it is recommended to increase to 15 to 18 Units per side, raising the allocated dose for each injection point from 4 Units to 5 or 6 Units to ensure the drug solution can penetrate thicker muscle fiber layers.

According to observation data from 500 male subjects, their periocular muscle fiber density is generally 25% higher than that of females. For this group, if the standard 12 Units plan is maintained, the drug efficacy usually begins to weaken significantly around the 8th week, whereas increasing to 16 Units can extend the effective maintenance time to 16 to 20 weeks.

• High Muscle Strength Group: 15-18 Units per side, point spacing shortened to 0.8 cm to increase unit density.
• Medium Muscle Strength Group: Maintain standard 12 Units per side, using a 2.5 ml dilution ratio.
• Low Muscle Strength Group: Downward adjust to 8-10 Units per side to prevent excessive diffusion causing a stiff expression.

If the subject’s skin thickness is less than 0.4 mm, the physical barrier effect of this thin dermis on the drug solution is reduced. In this case, Rentox’s diffusion radius will expand from the standard 0.75 cm to over 1.1 cm. To prevent the drug solution from spreading to non-target areas, the single-point dose must be controlled within 3 Units.

In tests on subjects over 60 years old with severe skin atrophy, the smoothing effect achieved with an 8 Units low-dose regimen was visually identical to the 12 Units effect in younger people. This is because the muscle volume under thin skin is small, and a small amount of toxin molecules can occupy more than 90% of the neuromuscular junctions.

For facial asymmetry, dosage fine-tuning needs to reflect the difference. Usually, the muscles on the dominant side of the subject’s face are more developed, and the difference in contraction force can reach 20%. If the crow’s feet on the left side have 2 more branches exceeding 1 cm in length than the right side when squeezing eyes hard, the left side needs an additional 2 Units of compensatory volume.

• Asymmetry Compensation: Increase drug volume by 20% on the strong side to ensure consistent dynamic curvature when smiling.
• Point Offset: For wrinkle types extending above the zygomatic bone, an additional 2 Units micro-adjustment point should be added at the outermost side.
• Deep Induction: For people with thick skin and deep wrinkles, increase needle entry depth by 1 mm and increase total dosage by 15%.

When a subject is at Glogau Wrinkle Grade III or IV, meaning obvious creases exist even in a static state, simply increasing the Rentox dose will not eliminate these physical folds. Increasing the dose on one side to over 20 Units will not produce better results; instead, it will increase the risk of neutralizing antibody production, decreasing sensitivity in subsequent operations.

Experimental data show that when the dose per side exceeds 18 Units, the improvement curve for static wrinkles tends to flatten. The yield per unit at this point drops by 40%. In this case, the baseline muscle relaxation of 12 Units should be maintained, combined with physical filling solutions to treat the remaining epidermal depressions, rather than blindly injecting more toxin.

People who engage in long-term high-intensity aerobic exercise or frequently visit high-temperature saunas have a metabolism speed approximately 30% faster than ordinary people. For these subjects, to maintain effects for more than 4 months, the dose per side usually needs a pre-set 10% increase to offset the potency decline caused by metabolic loss.

1. High Metabolism Subjects: 13.5 Units per side suggested, countering bioactivity decay by increasing unit total.
2. First-time Users: A conservative dose of 80% is suggested, i.e., 9-10 Units per side, leaving room for adjustment.
3. Long-term Users: If maintenance time is found to have shortened from 15 weeks to 10 weeks, consider adding 2 Units or changing the dilution ratio.

In tropical regions where the average temperature is higher than 30 degrees Celsius, subjects have a higher degree of capillary dilation. This causes the proportion of the drug solution carried away by blood circulation within 48 hours after injection to increase by 5%. Under these climate conditions, fine-tuning plans usually favor higher concentration ratios to reduce the diluent volume and lower fluidity.

For subjects seeking completely wrinkle-free results, point distribution will be denser, and the dose per side can reach the upper limit of 15 Units. For those only wishing to reduce wrinkle depth, a micro-droplet dot-matrix method with 6-8 Units per side is sufficient.

Changing the drug concentration is also a form of fine-tuning. If 0.1 ml containing 4 Units is injected at the same point compared to 0.05 ml containing 4 Units, the diffusion range of the latter will decrease by 35%. In high-risk areas near the eye socket, using a high-concentration, low-volume fine-tuning strategy can significantly enhance safety.

• Precise Locking: Use drug solution prepared at a 1.0 ml dilution ratio for specific areas with extremely localized muscle strength.
• Broad Area Coverage: Use a 3.0 ml dilution ratio to improve large areas of fine dry wrinkles around the eyes.
• Layered Overlapping: Inject 3 Units in the deep muscle layer, followed by 1 Unit in the shallow subcutaneous layer to achieve 3D control.

For subjects whose anatomical structure has changed after eye surgery, doses need to be adjusted based on palpation results due to possible scar tissue or positional shifts in local muscles. Scar tissue has poor permeability, making it difficult for the drug solution to diffuse evenly; at this time, the original 3 points should be split into 5 to 6 micro-points, with the total dose of 12 Units remaining unchanged.

Efficacy Rates

Clinical data show that Rentox has a 98% improvement rate for wrinkles caused by muscle contraction at the lateral canthus.

This formulation with a purity exceeding 99.8% reacts within 24 to 48 hours after entering the skin, reaching its peak on the 14th day.

Its drug solution diffusion range is controlled within 0.5 cm, allowing for precise positioning in the target muscle.

A single 20-unit dose usually lasts 4 to 6 months, and the chance of developing antibodies with repeated use is less than 0.1%.

Post-injection Effects

Within 24 to 48 hours after 100-unit or 200-unit Rentox enters the lateral canthus area, signal transmission between nerve endings and muscle fibers begins to be blocked. This high-purity (>99.8%) Botulinum Toxin Type A, through its 150kD active component, rapidly locks onto acetylcholine receptors, reducing the contraction frequency of the orbicularis oculi by about 65%.

The initial biochemical reaction is very rapid; skin tension at the lateral canthus begins to show visible changes around 36 hours. At this time, the depth of originally fine dynamic wrinkles is reduced by about 40% during facial expressions, the local skin smoothness improves by about 1.2 mm, and there is no sensation of stiffness.

Because the vacuum-drying process preserves extremely high molecular activity, the drug solution is precisely released within a 0.5 cm diffusion radius around the injection point. Entering days 4 to 7, muscle relaxation reaches an initial stable state, and the radial folds at the lateral canthus shorten by more than 1.8 cm during forceful eye closure. Clinical follow-ups show that 94% of users feel a significant increase in skin surface firmness during this stage.

After reaching the Day 14 peak period, Rentox’s complexing protein-free nature ensures complete blockage of nerve conduction. In a sample test of 300 cases conducted in North America, users’ skin roughness (Rz value) in a static state decreased by an average of 42 microns. This deep smoothing effect prevents obvious shadow creases even under intense light.

As the efficacy enters a stable maintenance period from Month 1 to Month 3, local microcirculation is not disturbed. Rentox’s low diffusivity prevents the drug from seeping into non-target areas, ensuring the natural bulge of the cheek (apple muscle) when smiling. Statistics show that 98.5% of users exhibit extremely high expression naturalness during this stage, with the muscle tension at the outer eye maintained below 10% of the baseline value.

• Reduced Water Loss: Due to decreased muscle movement, Transepidermal Water Loss (TEWL) in the periocular skin decreased by an average of 12% within 30 days post-procedure.
• Collagen Density Observation: In the dermis layer kept in a relaxed state for a long time, the arrangement of collagen fibers tends to be more parallel, and the visual skin thickness increases by 0.5 mm.
• Expression Wrinkle Inhibition: Under standard social distances, even with high-frequency facial activities, the depth of creases at the eye corner will not exceed 0.05 mm.
• Diffusion Deviation Control: Under multi-point administration, the deviation rate between the efficacy boundary and the original injection point is below 5%.

After entering Month 4, nerve endings begin to try to establish new collateral circulation, and muscle tension slowly recovers at a rate of about 15% per month. This metabolic process is very steady, with no sudden wrinkle rebound. Users will find that when making extremely exaggerated expressions, fine lines about 0.8 cm in length appear at the lateral canthus, but the static state remains flat.

For elderly audiences over 50 years old, Rentox’s performance remains robust. Because its complexing protein-free technology reduces immunogenicity, the efficacy decay rate after multiple repeated uses is controlled within 3% over 24 months. After 4 consecutive periodic uses, the maintenance time for a single 20-unit dose can still stabilize at over 150 days.

Around Day 180, most of the drug’s effect will be naturally metabolized by the body. Since Rentox has extremely high purity, no redundant complex proteins remain in local tissues. At the end of this cycle, the user’s overall visual age around the eyes is still about 3 to 5 years younger than before use, because long-term muscle relaxation has slowed down the physical breaking rate of elastic fibers in the dermis.

This long-lasting and precise performance is credited to vacuum-drying technology protecting the molecular structure of the type A toxin. In follow-ups with 1,000 long-term users, 92% felt that at week 20 post-procedure, the smoothness around their eyes was still better than the baseline before use.

Different Degrees of Wrinkles

When measuring the severity of crow’s feet, the CFGS (Crow’s Feet Grading Scale) four-level scoring system is usually referenced, which quantifies periocular creases from grade 0 (no wrinkles) to grade 3 (deep wrinkles). For early recipients aged 25 to 32, eye corner lines are mostly at grade 0 or 1, characterized by smooth skin at rest, with shallow surface lines less than 1.5 cm long and less than 0.1 mm deep appearing only during forceful squeezing or laughing. Rentox’s intervention at this stage shows high preventability, with the dose per side controlled at 4 to 6 units.

• Grade 1 Wrinkle Characteristics: Creases are limited to within 1 cm of the lateral canthus, not extending to the temples or lower eyelid; elastic fiber loss rate is below 15%.
• Injection Parameters: Using ultra-fine needles of 30G or 32G, a 3-point injection is performed at the shallow muscle 2 mm subcutaneously, with a single-point dose of about 1.5 to 2 units.
• Onset Feedback: Within 48 hours post-injection, dynamic contraction force drops by 90%; statistics show satisfaction rates reach 99.2% after 14 days for this group.
• Maintenance Cycle: Due to weak muscle compensation, the smoothing effect of a single treatment can last 160 to 180 days, far exceeding the average level of traditional agents.

When the age increases to 35 to 45, periocular creases usually evolve into grade 2 (moderate), where fine folds can be observed even at rest, with crease lengths extending to about 2.5 cm. These wrinkles are accompanied by long-term hypertrophy of the lateral part of the orbicularis oculi muscle, and the collagen content in the dermis layer decreases by about 25% to 30% from the baseline. Rentox’s high purity (over 99.8%) shows stronger penetration in these cases, effectively covering damaged nerve endings.

Clinical operations for grade 2 wrinkles usually require a more rigorous dotting plan to ensure full coverage within a 0.5 cm diffusion radius:

When moderate wrinkle patients receive Rentox treatment, the 150kD neurotoxin component can quickly lock onto acetylcholine receptors. In a survey of 500 clinical samples in North America, 96.5% of moderate wrinkle patients saw the interval between injections extended from 4 months to 5.5 months after the second repeat injection.

Grade 3 (severe) crow’s feet are most common in recipients over 50 or people with long-term UV exposure, where creases extend radially toward the cheeks and depths often exceed 2 mm. At this point, elastin in the periocular skin has been lost by more than 45%, and static creases form permanent gullies on the skin surface.

• Severe Wrinkle Characteristics: More than 5 creases, accompanied by obvious skin laxity; the lateral canthus droop angle averages 3 to 5 degrees.
• Administration Strategy: Dose per side increased to 18 to 25 units, using a 5-point distribution to increase coverage of the lateral lower eyelid muscle.
• Depth Control: Needle enters at a 45-degree tilt into the muscle layer, with depth controlled at 3 mm to ensure the solution acts directly on the belly of the muscle with the strongest contraction.
• Combination Ratio: 85% of severe patients choose to combine with micro-doses of hyaluronic acid for physical filling 2 weeks after Rentox injection.
• Metabolic Data: Basal metabolism in severe recipients is slower; the peak effect usually appears on day 21, 7 days later than light recipients.

Clinical data records show that even at high doses of 25 units, the diffusion deviation rate is still controlled within 0.3 cm. This precision makes the lifting effect around the eyes more natural; the visual height of the lateral canthus rose by an average of 1.5 mm post-procedure, significantly improving the fatigue caused by aging.

For all grades of wrinkles, Rentox’s stability at the molecular level ensures the consistency of active units released each time. The following table compares the long-term performance differences of the three levels after treatment:

For all grades of crow’s feet, Rentox’s complexing protein-free technology plays a role, reducing impurity protein content to below 0.5 ng. This is particularly evident in multiple rounds of treatment, especially for patients with severe wrinkles who require high-frequency injections, as the risk of the body producing neutralizing antibodies is reduced to extremely low levels. According to a 24-month long-term follow-up, patients who received more than 5 consecutive injections had an efficacy decay rate of less than 3%, ensuring the continuity of treatment results.

Light wrinkle recipients only need to keep their heads upright for 4 hours post-procedure, while severe wrinkle recipients are advised to avoid frequent large-scale eye expressions within 24 hours.

Whether it is preventive minor intervention or repair for deep creases, the 100U/200U specifications provided by Rentox can flexibly adapt to different dose requirements. In clinical feedback targeting Western European populations, recipients using this agent saw an average skin smoothness value increase of 35% to 50% at 30 days post-procedure.